[1] Lee K H, Ueng Y F, Wu C W, et al. The recommended dose ofertapenem poses a potential risk for central nervous system toxicity inhaemodialysis patients - case reports and literature reviews[J]. J Clin Pharm Ther,2015,40(2):240-244. [2] So taric N, Beovic B, Maticic M. Ertapenem-associated seizures in a patientwithout prior CNS disorder or severe renal dysfunction[J]. Int J Clin Pharmacol Ther,2014,52(3):255-258. [3] Duquaine S, Kitchell E, Tate T, et al. Central nervous system toxicity associated with ertapenemuse[J]. Ann Pharmacother,2011,45(1):e6. [4] Seto A H, Song J C, Guest S S. Ertapenem-associated seizures in a peritonealdialysis patient[J]. Ann Pharmacother, 2005,39(2):352-356. [5] Ong C, Chua A C, Tambyah P A, et al. Seizures associated with ertapenem[J]. Int J AntimicrobAgents, 2008,31(3):290. [6] Shea Y F, Mok M Y, Cheng K C, et al. Delayed recovery from ertapeneminduced encephalopathy:case-report and a possible mecha- nism[J]. Int J Clin Pharm,2013,5(4):535-537. [7] Oo Y, Packham D, Yau W, et al. Ertapenem-associated psychosis andencephalopathy[J]. Intern Med J,2014,44(8):817-819. [8] Apodaca K, Baker J, Bin-Bilal H, et al. Ertapenem-InducedDelirium: A Case Report and Literature Review[J].Psychosomatics,2015,56(5):561-566. [9] Fica A E, Abusada N J. Seizures associated with ertapenem use in patients with CNS disorders and renal insufficiency[J]. Scand J Infect Dis,2008,40(11-12):983-985. [10] 才旭,沈维. 厄他培南致谵妄症状3例并文献复习[J].中国新药与临志,2014,33(2):154-156. [11] 杨辉,张 ,邵宏. 慢性肾功能不全患者使用厄他培南致神经系统不良反应的药学监护及文献分析[J].中国新药杂志,2015,24(8):958-960. [12] 韩亚荣,周红丽,蒋数一,等. 慢性肾衰竭并发抗生素脑病诊治分析[J]. 中国全科医学,2012,15(5B):1625-1626. [13] 郑飞跃,吴燕,饶跃峰,等. 诺氏评估量表在药物不良反应评价中的作用及实例分析[J]. 中国药学杂志,2012,47(8):650-652. [14] Tomera K M, Burdmann E A, Pamo Reyna O G, et al. Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study[J]. Antimicrob Agents Chemother,2002,46(9):2895-2900. [15] Klugman K P, Dagan R. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group[J]. Antimicrob Agents Chemother,1995,39(5):1140-1146. [16] Grill M F, MagantiR K.Neurotoxic effects associated with antibiotic use: management considerations[J]. Br J Clin Pharmacol,2011, 72(3):381-393. [17] Chow K M, Hui a C, SzetoC C.Neurotoxicity induced by beta- lactam antibiotics: from bench to bedside[J]. Eur J Clin Microbiol Infect Dis,2005,24(10):649-653. [18] Grill M F, MagantiR. Cephalosporin-induced neurotox- icity: clinical manifestations, potential pathogenic mecha-nisms, and the role of electroencephalographic monitoring[J]. Ann Pharmacother,2008,42(12):1843-1850. [19] Koppel B S, Hauser W A, Politis C, et al. Seizures in the critically ill: the role of imipenem[J]. Epilepsia,2002,42(12):1590-1593. [20] Chow K M, Hui a C, Szeto C C. Neurotoxicity induced by beta- lactam antibiotics: from bench to bedside[J]. Eur J Clin Microbiol Infect Dis ,2005,24(10):649-653. [21] Grill M F, MagantiR. Cephalosporin-induced neurotox- icity: clinical manifestations, potential pathogenic mecha-nisms, and the role of electroencephalographic monitoring[J]. Ann Pharmacother, 2008,42(12):1843-1850. [22] Snavely S R, Hodges G R. The neurotoxicity of antibacterial agents[J]. Ann Intern Med,1984,101(1):92-104. [23] Liu X, Cheng M H, Shi C G, et al. Variability of glomerular filtration rate estimation equations in elderly Chinese patients with chronic kidney disease[J]. Clin Interv Aging,2012,7:409-415. |